Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

There is an unmet need for new treatments for idiopathic pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study in patients with IPF. This study design describes the subsequent pivotal phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Richeldi, Luca, Azuma, Arata, Cottin, Vincent, Kreuter, Michael, Maher, Toby M, Martinez, Fernando J, Oldham, Justin M, Valenzuela, Claudia, Gordat, Maud, Liu, Yi, Stowasser, Susanne, Zoz, Donald F, Wijsenbeek, Marlies S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Respiratory Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441083/
https://www.ncbi.nlm.nih.gov/pubmed/37597969
http://dx.doi.org/10.1136/bmjresp-2022-001563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441083/
https://www.ncbi.nlm.nih.gov/pubmed/37597969
http://dx.doi.org/10.1136/bmjresp-2022-001563

Ejemplares similares